Email - Alzheimer's Association welcomes FDA approval of lecanemab

Donate

Enews from the Alzheimer's Association

Having trouble viewing this message? You may view it as a web page. You may also view e-news archives.
To prevent mailbox filters from deleting your Alzheimer's Association email communications, please add alzheimers_enews@alz.org to your address book.

24/7 Helpline: 800.272.3900

Alzheimer’s Association welcomes FDA approval of lecanemab

The Alzheimer’s Association enthusiastically welcomes the U.S. Food and Drug Administration’s (FDA) action to grant the accelerated approval of lecanemab (Leqembi™) for the treatment of patients in the mild cognitive impairment (MCI) or mild dementia stage of Alzheimer’s disease and with confirmation of beta-amyloid. The Association also renews the urgent call for the Centers for Medicare & Medicaid Services to cover FDA-approved Alzheimer’s treatments.

Traumatic brain injury may increase risk of cognitive decline

Whether it's due to slipping on an icy sidewalk, a sports-related collision or even a mishap on the playground, bumps to the head are common. In the latest issue of ALZ magazine, experts discuss the relationship between the severity of traumatic brain injury and an increased risk of cognitive decline.

Help fight Alzheimer's

Give Now

Get Involved

Your Local Community

Find a chapter here

Alzheimer's affects people living with the disease in different ways

Alzheimer's typically progresses slowly in three general stages: mild (early stage), moderate (middle stage) and severe (late stage). Each person living with Alzheimer's will experience symptoms and progress through the stages of the disease in different ways.

More Resources:

Stages of Alzheimer's

Behaviors

Coping Strategies

Care Training


My Preferences:
Unsubscribe To stop receiving our weekly e-newsletter, simply unsubscribe.		Subscribe Was this e-newsletter forwarded to you? Subscribe to get it weekly.